Posts tagged with "FDA"

Waste is a terrible thing to waste: Ikea’s glossy (and free) new cookbook puts food scraps on the menu

April 6, 2021

Summery corncob soup, ‘plantcakes’ made with broccoli and carrot greens, and corn husk smoked chicken with fried corn silk are just a few of the inventive recipes in Ikea’s “The Scraps Book”—a cookbook dedicated to food preparation with the little things we usually throw away, The Chicago Tribune reports.

The Swedish home design brand collaborated with ten renowned chefs to address food waste and to show how easy it is to use food scraps like kale stems, banana peels and spent coffee grounds to create show-stopping meals. The beautifully designed ebook is full of stunning food photos of the 50 easy-to-follow recipes, along with tips like how to build your own backyard compost.

According to a Food and Drug Administration report, food waste is estimated at between 30% and 40% of the food supply in the United States, and the report lists wasted food as the single largest category of material placed in municipal landfills.

In 2016, the Department of Agriculture and Environmental Protection Agency announced the formation of the U.S. Food Loss and Waste 2030 Champions group and set a goal of reducing food waste by 50% by the year 2030, the Tribune notes.

.“ScrapsBook” is free for download at Apple Books, Google Play, and Ikea.com. The eBook is available to everyone, and Ikea Family members will be automatically entered to win a limited edition hardcover copy of the 214-page book. As Ikea says, “Waste is a terrible thing to waste”

Research contact: @chicagotribune

GlaxoSmithKline requests emergency authorization from FDA for COVID monoclonal antibody drug

March 29, 2021

On Friday, March 26, GlaxoSmithKline and Vir Biotechnology  applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug, CNBC reports.

The companies are requesting clearance for use by high-risk patients, age 12 and older.

The FDA submission is based on an interim analysis of a phase three trial that evaluated the drug for the early treatment of COVID-19 in adults at high risk of hospitalization. The drug reduced hospitalizations or death from COVID by 85% compared with a placebo. The trial results were based on 583 patients.

“As a result, the Independent Data Monitoring Committee recommended that the trial be stopped for enrolment due to evidence of profound efficacy,” the companies said in a statement.

The companies started testing the antibody on early-stage COVID patients in August, CNBC notes—hoping to keep symptoms from progressing. Antibody drugs gained attention after they were used to treat former President Donald Trump last year.

U.S. health officials say antibody drugs already authorized for use—from Regeneron and Eli Lilly—are being underutilized.

GSK said the companies will also continue discussions with the European Medicines Agency and other global regulators to make the drug available to COVID patients as soon as possible.

Research contact: @CNBC

Pfizer asks FDA to approve ‘not-so-cold storage’ for its vaccine

February 22, 2021

Pfizer announced on February 19 that  it is seeking permission from the Food and Drug Administration to store its COVID-19 vaccine for two weeks at temperatures that still are extremely cold, but that are commonly found in pharmaceutical freezers and refrigerators, CNBC reports.

The vaccine, which was developed with German drugmaker BioNTech, currently needs to be stored in ultra-cold freezers that keep it between minus 112 and minus 76 degrees Fahrenheit, according to the FDA.

Pfizer said it submitted new data to the U.S. agency that demonstrates that the vaccine is stable at between minus 13 and minus 5 degrees Fahrenheit, according to CNBC.

If the FDA grants the request, it could simplify logistics for distribution of the vaccine. U.S. federal and state officials are trying to pick up the pace of vaccinations as the virus spreads.

“We have been continuously performing stability studies to support the production of the vaccine at commercial scale, with the goal of making the vaccine as accessible as possible for healthcare providers and people across the [nation] and around the world,” Pfizer CEO Albert Bourla said in a release. “If approved, this new storage option would offer pharmacies and vaccination centers greater flexibility in how they manage their vaccine supply.”

Medical experts had warned that Pfizer’s vaccine would present logistical challenges because of the need for ultracold temperatures. In December, U.S. officials said they quarantined several thousand doses in California and Alabama after an “anomaly” in the transportation process caused the storage temperature to get too cold, CNBC notes.

The vaccine is shipped in a special thermal container that can be used as temporary storage for up to 30 days , if it is refilled with dry ice every five days. Before mixing with a saline diluent, the vaccine also may be refrigerated for up to five days at standard refrigerator temperature, between 36 degrees and 46 degrees Fahrenheit, according to the company.

By comparison, Moderna’s vaccine needs to be shipped at between minus 13 and minus 5 degrees Fahrenheit. It has said its vaccine remains stable at 36 to 46 degrees Fahrenheit, the temperature of a standard home or medical refrigerator, for up to 30 days. It can be stored for six months at minus 4 degrees Fahrenheit.

Johnson & Johnson’s vaccine, which is expected to be authorized for emergency use by the FDA as early as this month, has said it plans to ship its vaccine at 36 to 46 degrees Fahrenheit.

As additional stability data is obtained, Pfizer said it anticipates the shelf life could be extended, and alternate short-term temperature storage may be considered.

Research contact: @CNBC

 

Trump and friends got ‘special treatment’—COVID care that many Americans cannot access

December 11, 2020

HUD Secretary Ben Carson, former New Jersey Governor Chris Christie, and President Donald Trump are not the strongest candidates to survive the coronavirus: They are older, in some cases overweight, male, and not particularly fit. Yet all seem to have come through COVID-19—thanks to access to an antibody treatment that is in such short supply that some hospitals and states are doling it out by lottery, The New York Times reports.

Now RudyGiuliani, the latest member of President Trump’s inner circle to contract the coronavrius, has acknowledged that he received at least two of the same drugs the president received. He even conceded that his “celebrity” status had given him access to care that others did not have.

“If it wasn’t me, I wouldn’t have been put in a hospital frankly,” Giuliani, the president’s personal lawyer, told WABC radio in New York. “Sometimes when you’re a celebrity, they’re worried if something happens to you they’re going to examine it more carefully, and do everything right.”

According to the Times report, Giuliani’s candid admission once again exposes that COVID-19 has become a disease of the haves and the have-nots. The treatment given to President Trump’s allies is raising alarms among medical ethicists as state officials and health system administrators grapple with gut-wrenching decisions about which patients get antibodies in a system that can only be described as rationing.

We should not have Chris Christie and Ben Carson—and in the case of Carson, with intervention by the president—get access,” said Arthur Caplan, a medical ethicist who works with drug companies on how to ration scarce medicines, referring to the secretary of housing and urban development’s admission that the president “cleared” him for the therapy. “That is not the way to secure public support for difficult rationing systems.”

The treatments — a monoclonal antibody developed by Eli Lilly and a cocktail of two monoclonal antibodies developed by Regeneron — won emergency use authorization, or an E.U.A., from the Food and Drug Administration last month for outpatients with “mild to moderate” disease who are at high risk for progressing to severe disease or for being hospitalized.

With cases soaring, the pool of potential patients is vast.

“One of the challenges is the E.U.A. criteria really are so broad, it could be half of the people with COVID could qualify, but there is clearly not enough,” Erin Fox, the senior pharmacy director for University of Utah Health, who has helped her state draft criteria to determine who is eligible for the drugs, told the Times. “Unfortunately, that leaves each hospital or each state to develop their own rationing criteria.”

Even some top officials at the F.D.A —both career employees and political appointee —have privately expressed concern in recent months that people with connections to the White House appeared to be getting access to the antibody treatments, according to three senior administration officials.

Giuliani, 76, appeared unaware of the scarcity issues, telling interviewers that politicians have taken masks and business closures too far now that COVID-19 is “a treatable disease.”

Research contact: @nytimes

The buddy system: Provider of Trump COVID drug is president’s golf pal

October 11, 2020

New questions have emerged over the circumstances under which Donald Trump was prescribed an experimental antibody drug cocktail to treat his coronavirus infection now that the public knows that the source of the pharmaceuticals was the president’s golfing buddy.

As Trump wrongly hailed his treatment–which included a drug called REGN-COV2 produced by Tarrytown, New York-based Regeneron—as a “cure”, it emerged that the company’s CEO Leonard Schleifer  is a member of the Trump National Golf Club in Westchester County, New York, and had met the president in May to talk about drugs his company was developing The Guardian reports.

REGN-COV2 is a combination of two monoclonal antibodies designed to both treat people with coronavirus and to prevent Sars-CoV-2 infection. The antibodies are designed to prevent the coronavirus spike protein from attaching to Ace2 receptors in the body–the path the virus uses to infect people.

While some ethicists have defended Trump’s privileged access as president to experimental treatments, others have suggested it raises questions of fairness among other concerns, including his history of touting unproven treatments.

Trump’s relationship with Schleifer, whom he reportedly calls “Lenny,” adds to growing questions over the president’s almost exclusive access to experimental treatments unavailable to most other Americans, even as he has continued to downplay the threat of coronavirus based on his own experience.

The price of Regeneron stocks–which Trump has owned in the past–soared after it was revealed the drug had been made available for his treatment and Trump stated it would be made freely available for all, although he didn’t explain how.

“I call that a cure,” Trump said in a video, adding that everyone should have access to the not-yet-approved drug and that he would make sure it was in every hospital as soon as possible.

Trump’s comments were quickly criticized by doctors treating patients on the frontline of the COVID-19 pandemic in the United States.

Frankly, he is an anecdote, and he is an anecdote meaning he is one person who took this drug, but he has also taken dexamethasone,” said ER professional Dr Rob Davidson, who works in west Michigan, on Twitter.

Davidson added in his interview with the Guardian that Dexamethasone (a corticosteroid that prevents the release of substances in the body that cause inflammation) “makes you feel like a million bucks, it makes you feel like you’re on top of the world”.

He concluded: “Do everything the opposite of what this administration is telling you.”

After the president’s comments, Regeneron announced it had applied to the Food and Drug Administration (FDA) for an emergency use authorization.

“There are doses available for approximately 50,000 patients, and we expect to have doses available for 300,000 patients in total within the next few months,” the company said in a statement.

However, America is seeing more than 50,000 new cases of Covid-19 each day. Further, monoclonal antibody therapies are notoriously difficult to produce and expensive. The median cost of monoclonal antibody therapies approved over the last 20 years is more than $96,000 per treatment course.

Regeneron’s therapy has only been tested in 275 people, in a promising study that some scientists nevertheless said, “doesn’t cut it” for emergency use authorization.

The drug has also stirred debate because of how it was developed, The Guardian notes–using an “immortalized” cell line originally derived from an elective abortion in the Netherlands in the 1970s—a common process that the Trump administration opposes.

Republicans opposes embryonic stem cell research, according to the party platform.

The White House doctor, Sean Conley, said Trump had been given a single 8g dose that was made available under a compassionate use clause. Compassionate use requests are decided on a case-by-case basis—and both the drug company and the FDA must agree.

The Regeneron spokeswoman Alexandra Bowie said fewer than 10 of these requests had been granted, and with the drug in limited supply the priority was to use it in ongoing studies. Emergency access was granted “only in rare and exceptional circumstances”, she said.

Regeneron also contacted the Democratic presidential candidate, Joe Biden, to alert him to the availability of the drug under the compassionate use rule.

Alison Bateman-House, an ethicist at New York University Langone Health, told The Guardian that Regeneron’s overture to Biden should raise concerns.

“That crosses lines of appearing to promote a potentially unapproved product,” she told Associated Press, which would violate FDA rules. Rather than directing people to enrol in studies, she said it suggested that “we’ll cut the line for you”.

New questions have emerged over the circumstances under which Donald Trump was prescribed n experimental antibody drug cocktail to treat his coronavirus infection now that the public knows that the source of the pharmaceuticals was the president’s golfing buddy.

As Trump wrongly hailed his treatment–which included a drug called REGN-COV2 produced by Tarrytown, New York-based Regeneron—as a “cure”, it emerged that the company’s CEO Leonard Schleifer  is a member of the Trump National Golf Club in Westchester County, New York, and had met the president in May to talk about drugs his company was developing The Guardian reports.

REGN-COV2 is a combination of two monoclonal antibodies designed to both treat people with coronavirus and to prevent Sars-CoV-2 infection. The antibodies are designed to prevent the coronavirus spike protein from attaching to Ace2 receptors in the body–the path the virus uses to infect people.

While some ethicists have defended Trump’s privileged access as president to experimental treatments, others have suggested it raises questions of fairness among other concerns, including his history of touting unproven treatments.

Trump’s relationship with Schleifer, whom he reportedly calls “Lenny,” adds to growing questions over the president’s almost exclusive access to experimental treatments unavailable to most other Americans, even as he has continued to downplay the threat of coronavirus based on his own experience.

The price of Regeneron stocks–which Trump has owned in the past–soared after it was revealed the drug had been made available for his treatment and Trump stated it would be made freely available for all, although he didn’t explain how.

“I call that a cure,” Trump said in a video, adding that everyone should have access to the not-yet-approved drug and that he would make sure it was in every hospital as soon as possible.

Trump’s comments were quickly criticized by doctors treating patients on the frontline of the COVID-19 pandemic in the United States.

Frankly, he is an anecdote, and he is an anecdote meaning he is one person who took this drug, but he has also taken dexamethasone,” said ER professional Dr Rob Davidson, who works in west Michigan, on Twitter.

Davidson added in his interview with the Guardian that Dexamethasone (a corticosteroid that prevents the release of substances in the body that cause inflammation) “makes you feel like a million bucks, it makes you feel like you’re on top of the world”.

He concluded: “Do everything the opposite of what this administration is telling you.”

After the president’s comments, Regeneron announced it had applied to the Food and Drug Administration (FDA) for an emergency use authorization.

“There are doses available for approximately 50,000 patients, and we expect to have doses available for 300,000 patients in total within the next few months,” the company said in a statement.

However, Americais seeing more than 50,000 new cases of Covid-19 EaCH day. Further, monoclonal antibody therapies are notoriously difficult to produce and expensive. The median cost of monoclonal antibody therapies approved over the last 20 years is more than $96,000 per treatment course.

Regeneron’s therapy has only been tested in 275 people, in a promising study that some scientists nevertheless said, “doesn’t cut it” for emergency use authorization.

The drug has also stirred debate because of how it was developed, The Guardian notes–using an “immortalized” cell line originally derived from an elective abortion in the Netherlands in the 1970s—a common process that the Trump administration opposes.

Republicans opposes embryonic stem cell research, according to the party platform.

The White House doctor, Sean Conley, said Trump had been given a single 8g dose that was made available under a compassionate use clause. Compassionate use requests are decided on a case-by-case basis—and both the drug company and the FDA must agree.

The Regeneron spokeswoman Alexandra Bowie said fewer than 10 of these requests had been granted, and with the drug in limited supply the priority was to use it in ongoing studies. Emergency access was granted “only in rare and exceptional circumstances”, she said.

Regeneron also contacted the Democratic presidential candidate, Joe Biden, to alert him to the availability of the drug under the compassionate use rule.

Alison Bateman-House, an ethicist at New York University Langone Health, told The Guardian that Regeneron’s overture to Biden should raise concerns.

“That crosses lines of appearing to promote a potentially unapproved product,” she told Associated Press, which would violate FDA rules. Rather than directing people to enrol in studies, she said it suggested that “we’ll cut the line for you”.

Research contact: @GuardianUS

Roll Call exclusive: States plan to independently vet COVID-19 vaccine data

September 18, 2020

Governors, including New York’s Andrew Cuomo, are publicly raising doubts about the FDA’s and the CDC’s ability to withstand pressure from President Donald Trump to develop a coronavirus vaccine at warp speed, Roll Call reported exclusively on September 17.

Those same officials are expressing skepticism about federal reviews of potential COVID-19 vaccines—with some going so far as to plan to independently analyze clinical trial data before distributing a vaccine, in a sign of how sharply trust in federal health agencies has fallen this year.

The wariness—which public health experts call highly unusual if not unprecedented—could undercut the goal of a cohesive national immunization strategy and create a patchwork of efforts that may sabotage hopes of containing the coronavirus.

State plans to review the data indicate how deeply any appearance of political meddling could disrupt vaccination and cost lives Roll Call says.

And it’s not a surprise that some red states appear more likely to rely on the Trump Administration, while blue states may scour the data and be more cautious about vaccinating their residents immediately.

CQ Roll Call contacted state health departments in 50 states and the District of Columbia and received substantive responses from a dozen:

  • Seven jurisdictions indicated that they would analyze the data independently: California, Colorado, the District of Columbia, Michigan, New York, Oregon and West Virginia.
  • Another two—Montana and Wyoming—said they would only administer a vaccine that completed clinical trials and an outside committee’s review.
  • Three states —Arizona, Georgia and Oklahoma— indicated they would accept federal recommendations as usual.

 “The president says he’s going to have a vaccine. CDC is talking about a vaccine in early November. How convenient. It’s going to be an Election Day miracle drug,” New York Gov. Andrew Cuomo, a Democrat, said earlier this month.

Cuomo referenced the FDA’s emergency use authorization earlier this year of a drug touted by Trump, hydroxychloroquine, which the agency later withdrew after finding the drug was not effective against COVID-19 and could lead to dangerous heart conditions. “Some people are concerned that the vaccine may wind up being hydroxychloroquine,” he said, adding that the state health department will review the research before recommending that New Yorkers take any vaccine.

Nearly 200,000 Americans have died of COVID-19, according to the Johns Hopkins University School of Medicine.

Research contact: @rollcall

A shot in the dark? Drug companies issue rare joint pledge on vaccine safety

September 9, 2020

On September 7, nine pharmaceutical companies issued a rare joint pledge—intended to reassure the American public about the safety and efficacy of the coronavirus vaccines that currently are under development.

The statement from the top drug companies working on COVID-19 vaccines—including Pfizer, AstraZeneca, and Moderna—comes amid fears that President Donald Trump will continue to place pressure on the industry to speed up the vaccine approval process without proper oversight, and doubts among the public about taking a vaccine, The Hill reports.

The joint pledge states that the companies will not seek Food and Drug Administration (FDA) approval for their vaccines until a rigorous phase 3 clinical trial shows that it is safe and that it works. 

The companies pledged they would “only submit for approval or emergency use authorization after demonstrating safety and efficacy through a Phase 3 clinical study that is designed and conducted to meet requirements of expert regulatory authorities such as FDA.”

The companies said they would “always make the safety and well-being of vaccinated individuals our top priority.”

Highlighting the fears of political interference, Trump on Monday floated the idea of having a vaccine before Election Day on November 3. “We’re going to have a vaccine very soon. Maybe even before a very special date. You know what date I’m talking about,” he said at a news conference.

Trump has put pressure on the FDA before, saying that the “deep state” at the agency was throwing up roadblocks before the agency issued an emergency authorization for a coronavirus treatment known as convalescent plasma.

According to The Hill, FDA Commissioner Stephen Hahn also has offered reassurances that his agency will base vaccine decisions only on science and not on politics.

But the statement from the pharmaceutical companies is an illustration of how deep the fears are about politicization of the process and the need for companies to try make their own reassurance about science guiding the process.

An NPR-PBS NewsHour-Marist poll last month found that a significant portion of the public (35%) did not intend to receive a coronavirus vaccine.

Research contact: @thehill

FDA alert: At least 75 brands of hand sanitizer contain methanol—and may be toxic

July 27, 2020

Federal regulators have recalled dozens of hand sanitizers—many of them, widely available through Walmart, Costco, and other national retailers—because they contain dangerous and potentially fatal levels of wood alcohol (also known as methanol).

Specifically, the Food and Drug Administration (FDA) has identified at least 75 brands whose labels say they contain ethanol (also known as ethyl alcohol or grain alcohol)—but later proved to contain methanol.

The FDA recommends that consumers should immediately stop using these hand sanitizers and dispose of the bottle in a hazardous waste container, if available, or dispose of as recommended by your local waste management and recycling center. Do not flush or pour these products down the drain or mix with other liquids.

Methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system or death.

Although people using these products on their hands are at risk for methanol poisoning, young children who accidentally ingest these products and adolescents and adults who drink these products as an alcohol (ethanol) substitute are most at risk. Consumers who have been exposed to hand sanitizer containing methanol and are experiencing symptoms should seek immediate medical treatment for potential reversal of toxic effects of methanol poisoning.

. While methanol-containing hand sanitizers are more life-threatening than others, the FDA urges all consumers not to drink any hand sanitizer product. This is particularly important for young children, especially toddlers, who may be attracted by the pleasant smell or brightly colored bottles. During the pandemic, poison control centers have had an increase in calls about accidental ingestion of hand sanitizer, and it is important that adults keep these products out of reach of children and monitor young children’s use.

Do not use hand sanitizer on pets or allow pets to swallow hand sanitizer. If you believe your pet has eaten something potentially dangerous, call a veterinarian or a pet poison control center immediately.

Consumers are reminded to wash their hands often with soap and water for at least 20 seconds, especially after going to the bathroom; before eating; and after coughing, sneezing or blowing one’s nose. If soap and water are not readily available, the U.S. Centers for Disease Control and Prevention (CDC) recommends consumers use an alcohol-based hand sanitizer that contains at least 60% ethanol.

The FDA encourages health care professionals, consumers and patients to report adverse events or quality problems experienced with the use of hand sanitizers to FDA’s MedWatch Adverse Event Reporting program (please provide the agency with as much information as possible to identify the product):

  • Complete and submit the report online, or
  • Download and complete the form, then submit it via fax at 1-800-FDA-0178.

Consumers, manufacturers or distributors who have questions for the FDA regarding hand sanitizers should email COVID-19-Hand-Sanitizers@fda.hhs.gov.

Research contact: @US_FDA

Kroger Health’s home coronavirus test kit cleared for emergency use by FDA

July 2, 2020

Kroger  has received Emergency Use Authorization from the Food and Drug Administration for a home COVID-19 test, The Street reports.

“The testing solution combines the safety and convenience of at-home sample collection with the expert guidance of a telehealth consultation to help improve the quality of the collection process,” the country’s largest grocery store chain, based in Cincinnati, Ohio, said in a statement.

The kit initially will be available for Kroger workers, based on medical need, beginning this week. Kroger is partnering with clinical laboratory Gravity Diagnostics.

According to The Street, the company plans to rapidly expand the availability of the kits to other companies and organizations in the coming weeks, with a goal of processing up to 60,000 tests per week by the end of July.

“Over the past few months, Kroger Health has been providing Americans with access to Covid-19 testing through community test sites across the country,” said Colleen Lindholz, president.

“However, we’ve observed some individuals do not have access to transportation or live near these community testing locations. To help ease this burden and provide greater accessibility, we will be offering a home testing solution.”

A licensed healthcare professional will supervise the tests. “The process is simple and is available at no cost to eligible patients who meet established clinical criteria for likely Covid-19 infection or exposure,” Kroger said.

The kit includes a nasal swab, transport vial, instruction sheet, prepaid shipping label, and packing materials for return shipment of the sample to the laboratory.

Research contact: @TheStreet

Cuomo: Millions and millions of tests needed before U.S. economy can be rebooted

April 13, 2020

New York Governor Andrew Cuomo said on April 10 that millions of COVID-19 tests must be administered nationwide, if the country’s economy is going to reopen safely and effectively, according to a report by The Hill.

“This is going to be a horrendous transformational period for us,” Cuomo said in an appearance on MSNBC‘s Morning Joe.

“I don’t think we ever get back to normal. I think this is one of the new normals now in public health,” he said.

The governor added that just how smoothly American society and its economy will be able to reopen will directly correspond to what the steps the government does or does not take.

“This is such an important period for government and the political discussion,” Cuomo said. “Nothing is pre-charted here. It’s all a function of what we do.”

He added: “How good are we at getting this testing up? Are we better than we’ve been in the past? Is it going to take us months to come to scale on rapid testing? That’s the only way to get people back to work. You have to have millions and millions of tests, frankly, better and faster than we’ve done to date.”

This isn’t the first time that Cuomo has signaled that widespread testing to see who has had the virus is essential to America’s ability to get its people back to work, The Hill said.

Cuomo has said that New York State has developed a test that sees whether a person has developed antibodies to fight COVID-19. It has been well-documented that not everyone who contracted the virus will show outward symptoms consistent with the disease.

“We cannot restart life as we knew it without testing,” he tweeted earlier this week.

But Cuomo’s stance on testing differs from President Trump’s opinion on the matterThe Hill noted. In his daily coronavirus press briefing Thursday, Trump punted when asked about the need for widespread testing—saying that it would be nice but not required.

“We want to have it and we’re going to see if we have it. Do you need it? No. Is it a nice thing to do? Yes,” Trump said. “We’re talking about 325 million people. And that’s not going to happen, as you can imagine, and it would never happen with anyone else either.” 

Trump has expressed optimism that the country could start to ease social distancing recommendations by early May. The White House’s social distancing guidelines run through the end of April.

Cuomo isn’t alone in his call for comprehensive testing, though.

“In a setting where there will still be spread and we’ll still be slowly exiting the epidemic; we need capacity to test several million people a week (and probably more) to get broad enough coverage in community to detect outbreaks early and make case containment strategies work,” Scott Gottlieb, Trump’s former Food and Drug Administration commissioner, tweeted Thursday.

According to the COVID Tracking Project, the United States has tested about 960,000 people in the past week.

Research contact: @thehill